Literature DB >> 33147336

B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia.

Craig S Boddy1, Brent T Tan2, Joseph Aoki3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33147336      PMCID： PMC7656922          DOI： 10.1182/bloodadvances.2020003109

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature.

Authors:  M A Elliott; C A Hanson; G W Dewald; S A Smoley; T L Lasho; A Tefferi
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

Review 2.  Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.

Authors:  Natasha Szuber; Michelle Elliott; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-12-30       Impact factor: 10.047

3.  Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Authors:  Arief S Gunawan; Donal P McLornan; Bridget Wilkins; Katherine Waghorn; Yvette Hoade; Nicholas C P Cross; Claire N Harrison
Journal:  Haematologica       Date:  2017-03-16       Impact factor: 9.941

4.  Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

Authors:  T L Lasho; A Mims; M A Elliott; C Finke; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

5.  ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.

Authors:  Michelle A Elliott; Animesh Pardanani; Curtis A Hanson; Terra L Lasho; Christy M Finke; Alem A Belachew; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-07       Impact factor: 10.047

6.  Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Authors:  Maximilian Stahl; Mina L Xu; David P Steensma; Raajit Rampal; Melissa Much; Amer M Zeidan
Journal:  Ann Hematol       Date:  2016-04-11       Impact factor: 3.673

7.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

8.  CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Authors:  Natasha Szuber; Christy M Finke; Terra L Lasho; Michelle A Elliott; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-15       Impact factor: 11.037

9.  CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib.

Authors:  Marc S Schwartz; Matthew J Wieduwilt
Journal:  Leuk Res Rep       Date:  2020-06-08

10.  Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.

Authors:  Anna Hinze; Jenny Rinke; Andreas Hochhaus; Thomas Ernst
Journal:  Ann Hematol       Date:  2020-06-23       Impact factor: 3.673
View more
  2 in total

1.  Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.

Authors:  Franziska C Adam; Jakub Szybinski; Jörg P Halter; Nathan Cantoni; Friedel Wenzel; Katharina Leonards; Sime Brkic; Jakob R Passweg; Ivo Touw; Julia E Maxson; Sara C Meyer
Journal:  Curr Oncol       Date:  2022-02-01       Impact factor: 3.109

Review 2.  Chronic Neutrophilic Leukemia: A Literature Review of the Rare Myeloproliferative Pathology.

Authors:  Vishwanath Anil; Harpreet Gosal; Harsimran Kaur; Hyginus Chakwop Ngassa; Khaled A Elmenawi; Lubna Mohammed
Journal:  Cureus       Date:  2021-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.